Ipsen: Combined Shareholders’ Meeting of 28 May 2019
May 07 2019 - 12:36PM
Business Wire
Availability and Consultation of Preparatory
Documents for the Shareholders’ Meeting
Regulatory News:
The Shareholders of the Company are invited to participate in
the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR:
IPSEY) to be held on Tuesday 28 May 2019 at 3 pm (Paris time) at
the Salons de l’Hôtel des Arts et Métiers, 9 bis avenue d’Iéna,
75116 Paris, France.
The preliminary notice of meeting was published in the Bulletin
des Annonces Légales Obligatoires (BALO) of 17 April 2019 and the
notice of meeting will be published in the BALO on 8 May 2019.
These documents, as well as the Convening notice (including, in
particular, the agenda, the proposed resolutions and the conditions
regarding attendance and vote), are also available on Ipsen’s
website at the following address: www.ipsen.com, under the
“Investors/Shareholders’ meetings” section.
The Shareholders will be asked to approve in particular the
following resolutions:
- The approval of a dividend of €1.00 per
share for the financial year 2018, the ex-date being set on 31 May
2019 and the dividend payment on 4 June 2019;
- The renewal of the terms of office as a
Director of Mr. Marc de Garidel, Henri Beaufour andMs. Michèle
Ollier for 4 years, maintaining the independence Directors’ rate at
a third in accordance with the Afep-Medef Code and each gender’s
proportion at more than 40% in accordance with the law (the
Director representing the employees being not taken into account in
these rates).
Documents and information relating to this Meeting will be made
available to shareholders under the legal and regulatory conditions
in force.
In accordance with applicable regulatory provisions:
- Registered shareholders may, up to the
fifth day (inclusive) before the Meeting, request from the Company
to send these documents, where appropriate at his/her express
request by electronic means. For holders of bearer shares, the
exercise of this right is subject to the presentation of a
shareholding certificate (attestation de participation) in the
bearer securities accounts managed by the authorized
intermediary.
- Any shareholder may consult these
documents at the Company’s headquarters.
About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group
focused on innovation and Specialty Care. The group develops and
commercializes innovative medicines in three key therapeutic areas
- Oncology, Neuroscience and Rare Diseases. Its commitment to
Oncology is exemplified through its growing portfolio of key
therapies for prostate cancer, neuroendocrine tumors, renal cell
carcinoma and pancreatic cancer. Ipsen also has a wellestablished
Consumer Healthcare business. With total sales over €2.2 billion in
2018, Ipsen sells more than 20 drugs in over 115 countries, with a
direct commercial presence in more than 30 countries. Ipsen's
R&D is focused on its innovative and differentiated
technological platforms located in the heart of the leading
biotechnological and life sciences hubs (Paris-Saclay, France;
Oxford, UK; Cambridge, US). The Group has about 5,700 employees
worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the
United States through a Sponsored Level I American Depositary
Receipt program (ADR: IPSEY). For more information on Ipsen, visit
www.ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190507005873/en/
MediaChristian MarcouxSenior Vice President,
Global Communications+33 (0)1 58 33 67
94christian.marcoux@ipsen.com
Fanny AllaireDirector, Ipsen France Hub, Global
Communications+33 (0)1 58 33 58
96fanny.allaire@ipsen.com
Financial CommunityEugenia LitzVice President,
Investor Relations+44 (0) 1753 627721eugenia.litz@ipsen.com
Myriam KoutchinskyInvestor Relations Manager+33 (0)1 58
33 51 04myriam.koutchinsky@ipsen.com
Ipsen (EU:IPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ipsen (EU:IPN)
Historical Stock Chart
From Apr 2023 to Apr 2024